Jafron Biomedical Income Statement

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '26 Sep 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Jan '23 Jan 1, 2023	Jan '22 Jan 1, 2022
Operating Revenue	2,062	2,007	2,670	1,919	2,487	2,671
Other Revenue	4.7	4.7	7.33	3.42	4.54	4.5
Revenue	2,066	2,012	2,677	1,922	2,491	2,675
Revenue Growth	1.41%	-24.86%	39.27%	-22.84%	-6.88%	37.15%
Cost of Revenue	466.28	440.4	520.26	390.89	440.36	402.12
Gross Profit	1,600	1,571	2,157	1,531	2,051	2,273
Selling, General & Admin	524.29	633.15	881.19	787.89	838.78	729.46
Research & Development	207.76	198.45	240.09	245.38	253.91	173.77
Other Operating Expenses	39.49	32.17	37.29	24.61	33.72	39.56
Operating Expenses	775.11	862.83	1,159	1,048	1,124	949.55
Operating Income	824.96	708.59	997.98	482.98	926.66	1,324
Interest Expense	-50.92	-53.51	-63.71	-54.33	-36.04	-8.91
Interest & Investment Income	69.61	67.95	73.09	87.96	63.79	56.5
Currency Exchange Gain (Loss)	-2.17	-2.17	0.78	1.22	1.07	-0.81
Other Non Operating Income (Expenses)	32.39	2.01	-1.73	-2.12	-0.5	-5.34
EBT Excluding Unusual Items	873.87	722.86	1,006	515.71	954.97	1,365
Impairment of Goodwill	-	-	-5.2	-25.61	-6.26	-
Gain (Loss) on Sale of Investments	-2.77	0.01	1.02	-	-0.01	0.01
Gain (Loss) on Sale of Assets	2.76	-0.08	3.64	6.72	0.86	0.98
Asset Writedown	-72.2	-53.59	-1.04	-1.46	-1.61	-1.15
Other Unusual Items	-18.31	-9.08	2.13	25.66	68.85	42.14
Pretax Income	783.35	660.13	1,007	521.02	1,017	1,407
Income Tax Expense	127.39	128.46	192.78	95.3	135.86	211.38
Earnings From Continuing Operations	655.96	531.67	814.19	425.72	880.95	1,196
Minority Interest in Earnings	-1.72	1.15	6.01	10.77	8.62	0.97
Net Income	654.24	532.82	820.2	436.49	889.56	1,197
Net Income to Common	654.24	532.82	820.2	436.49	889.56	1,197
Net Income Growth	35.79%	-35.04%	87.91%	-50.93%	-25.67%	36.74%
Shares Outstanding (Basic)	778	772	781	794	794	803
Shares Outstanding (Diluted)	778	772	781	794	794	803
Shares Change	1.71%	-1.14%	-1.57%	-0.08%	-1.12%	-0.89%
EPS (Basic)	0.84	0.69	1.05	0.55	1.12	1.49
EPS (Diluted)	0.84	0.69	1.05	0.55	1.12	1.49
EPS Growth	33.51%	-34.29%	90.91%	-50.89%	-24.83%	37.96%

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '26 Sep 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Jan '23 Jan 1, 2023	Jan '22 Jan 1, 2022
Free Cash Flow	707.88	548.63	815.85	669.49	407.91	712
Free Cash Flow Per Share	0.91	0.71	1.04	0.84	0.51	0.89
Dividend Per Share	0.520	0.520	0.800	0.400	0.670	0.900
Dividend Growth	-35.00%	-35.00%	100.00%	-40.30%	-25.56%	36.36%
Gross Margin	77.44%	78.11%	80.57%	79.67%	82.33%	84.97%
Operating Margin	39.92%	35.22%	37.28%	25.12%	37.19%	49.48%
Profit Margin	31.66%	26.48%	30.64%	22.71%	35.70%	44.73%
Free Cash Flow Margin	34.26%	27.27%	30.47%	34.83%	16.37%	26.61%
EBITDA	937.06	825.76	1,122	573.43	995.72	1,373
EBITDA Margin	45.35%	41.05%	41.90%	29.83%	39.97%	51.32%
D&A For EBITDA	112.1	117.16	123.92	90.44	69.07	49.25
EBIT	824.96	708.59	997.98	482.98	926.66	1,324
EBIT Margin	39.92%	35.22%	37.28%	25.12%	37.19%	49.48%
Effective Tax Rate	16.26%	19.46%	19.14%	18.29%	13.36%	15.02%
Revenue as Reported	2,066	2,012	2,677	1,922	2,491	2,675